<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pediatr Rheumatol Online J</journal-id><journal-id journal-id-type="iso-abbrev">Pediatr Rheumatol Online J</journal-id><journal-title-group><journal-title>Pediatric Rheumatology Online Journal</journal-title></journal-title-group><issn pub-type="epub">1546-0096</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3334078</article-id><article-id pub-id-type="publisher-id">1546-0096-6-S1-P27</article-id><article-id pub-id-type="doi">10.1186/1546-0096-6-S1-P27</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Efficacy, safety and effect on gene expression profiling of anakinra in systemic-onset juvenile idiopathic arthritis: final results of a randomised, double-blind, placebo-controlled trial (ANAJIS)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Quartier</surname><given-names>P</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Allantaz</surname><given-names>F</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Cimaz</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Pillet</surname><given-names>P</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Richer</surname><given-names>O</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Desjonqueres</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Duquesne</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Messiaen</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Bardin</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Bossuyit</surname><given-names>X</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Boutten</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Bienvenu</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>Menoni</surname><given-names>V</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A14"><name><surname>Sotou-Bere</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A15"><name><surname>Neven</surname><given-names>B</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A16"><name><surname>Mahloui</surname><given-names>N</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A17"><name><surname>Mogenet</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A18"><name><surname>Kassai</surname><given-names>B</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A19"><name><surname>Chaussabel</surname><given-names>D</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A20"><name><surname>Treluyer</surname><given-names>JM</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A21"><name><surname>Bresson</surname><given-names>JL</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A22"><name><surname>Landais</surname><given-names>P</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A23"><name><surname>Pascual</surname><given-names>V</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib></contrib-group><aff id="I1"><label>1</label>Necker-Enfants Malades, Assistance Publique Hopitaux de Paris, Paris, France</aff><aff id="I2"><label>2</label>Baylor Institude, Dallas, USA</aff><aff id="I3"><label>3</label>Edouard Herriot, Lyon, France</aff><aff id="I4"><label>4</label>Pellegrin, Bordeaux, France</aff><aff id="I5"><label>5</label>Hotel Dieu, Paris, France</aff><aff id="I6"><label>6</label>University of Leuwen, Leuwen, Belgium</aff><aff id="I7"><label>7</label>Bichat, Assistance Publique Hopitaux de Paris, Paris, France</aff><aff id="I8"><label>8</label>Laboratoire d'Immunologie Lyon sud, Lyon, France</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>15</day><month>9</month><year>2008</year></pub-date><volume>6</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">15th Paediatric Rheumatology European Society (PreS) Congress</named-content><named-content content-type="supplement-editor">Wietse Kuis, Patricia Woo, Angelo Ravelli, Hermann Girschick, Micha&#x000eb;l Hofer, Johannes Roth, Rotraud K Saurenmann, Alberto Martini, Pavla Dolezova, Janjaap van der Net, Pierre Quartier, Lucy Wedderburn and Jan Scott</named-content></supplement><fpage>P27</fpage><lpage>P27</lpage><permissions><copyright-statement>Copyright &#x000a9;2008 Quartier et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Quartier et al; licensee BioMed Central Ltd.</copyright-holder></permissions><self-uri xlink:href="http://www.ped-rheum.com/content/6/S1/P27"/><conference><conf-date>14-17 September 2008</conf-date><conf-name>15th Paediatric Rheumatology European Society (PreS) Congress</conf-name><conf-loc>London, UK</conf-loc></conference></article-meta></front><body><sec><title>Purpose</title><p>To investigate efficacy and safety of anakinra in systemic-onset juvenile idiopathic arthritis patients. To assess treatment effect on gene expression profiling, immune response to anti-pneumococcal Pneumo23 vaccine, serum amyloid A level, serum ferritin level and the percentage of glycosylated ferritin.</p></sec><sec sec-type="methods"><title>Methods</title><p>Multicenter randomized double-blind trial. The primary objective was to compare the efficacy of a one-month treatment with anakinra to a placebo between 2 groups of 12 patients each. Response was defined by 30% improvement of pediatric ACR core-set criteria for JIA, resolution of fever and systemic symptoms and normalization or a decrease of at least 50% of both CRP and first hour ESR compared to baseline. Intention-to-treat analysis. Secondary objectives included tolerance and efficacy assessment over 12 months and treatment effect on blood gene expression profiling.</p></sec><sec><title>Results</title><p>At one month, there was a significant difference in the response rate between patients treated with anakinra (8/12) and placebo (1/12). During the double-blind phase, the number of adverse events, mainly pain to injections, was similar between both groups. Ten patients from the placebo group switched to anakinra at Month 1 and 9 were responders at month 2. Eight patients discontinued anakinra before Month 12: painful injections during the double-blind phase (2 patients, both on placebo), ileocolic symptoms leading to the diagnosis of Crohn's disease (1 patient), transient hepatic cytolysis (one case), lack of efficacy or a disease flare (4 cases). Gene expression profile analyses showed a set of gene pathways dysregulated in SOJIA whose expression dramatically changed upon anakinra treatment.</p></sec></body></article>